Why the study?
Does intravenous azimilide prolong action potential duration without reverse use-dependence in open-chest dogs?
Does intravenous azimilide prolong action potential duration without reverse use-dependence in open-chest dogs?
In a canine model, azimilide prolongs action potential duration even at very short cycle lengths without reverse use-dependence, suggesting potential efficacy during tachycardia.
No takes yet. Share an insight, caveat, or question.
May inform antiarrhythmic development targeting rate-independent APD effects; leaves open translation to human trials.
Qi et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: